Merck ends development of BTK inhibitor nemtabrutinib
Finance Desk
Merck ends development of BTK inhibitor nemtabrutinib | Seeking Alpha
JasonDoiy
Merck (MRK) has abandoned development of the oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor nemtabrutinib after a Data Monitoring Committee evaluating a phase 3 trial suggested the benefits of the therapy may not outweigh the risks.